Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May 28:9:120.
doi: 10.1186/1748-717X-9-120.

The efficacy of stereotactic body radiation therapy on huge hepatocellular carcinoma unsuitable for other local modalities

Jenny Y Que  1 , Li-Ching Lin, Kuei-Li Lin, Chia-Hui Lin, Yu-Wei Lin, Ching-Chieh Yang
Affiliations

The efficacy of stereotactic body radiation therapy on huge hepatocellular carcinoma unsuitable for other local modalities

Jenny Y Que et al. Radiat Oncol. .

Abstract

Background and aim: To evaluate the safety and efficacy of Cyberknife stereotactic body radiation therapy (SBRT) and its effect on survival in patients with unresectable huge hepatocellular carcinoma (HCC) unsuitable of other standard treatment option.

Methods: Between 2009 and 2011, 22 patients with unresectable huge HCC (≧10 cm) were treated with SBRT. dose ranged from 26 Gy to 40 Gy in five fractions. Overall survival (OS) and disease-progression free survival (DPFS) were determined by Kaplan-Meier analysis. Tumor response and toxicities were also assessed.

Results: After a median follow-up of 11.5 month (range 2-46 months). The objective response rate was achieved in 86.3% (complete response (CR): 22.7% and partial response (PR): 63.6%). The 1-yr. local control rate was 55.56%. The 1-year OS was 50% and median survival was 11 months (range 2-46 months). In univariate analysis, Child-Pugh stage (p = 0.0056) and SBRT dose (p = 0.0017) were significant factors for survival. However, in multivariate analysis, SBRT dose (p = 0.0072) was the most significant factor, while Child-Pugh stage of borderline significance. (p = 0.0514). Acute toxicities were mild and well tolerated.

Conclusion: This study showed that SBRT can be delivered safely to huge HCC and achieved a substantial tumor regression and survival. The results suggest this technique should be considered a salvage treatment. However, local and regional recurrence remain the major cause of failure. Further studies of combination of SBRT and other treatment modalities may be reasonable.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The 1-yr local control rate and regional control rate from Cyberknife SBRT.
Figure 2
Figure 2
(A) Overall survival rate and (B) Disease progression-free survival rate from Cyberknife SBRT. The 1-yr. Overall survival rates and median survival time were 50% and 11 months, respectively. The 1 -yr. Disease progression-free survival rate and median disease-progression free survival rate were 31.8% and 6 months, respectively.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Cutsem EV, Singh H, Chow WC, Ooi LL, Chow P, Khin MW, Koo WH. Management of hepatocellular carcinoma in Asia: consensus statement from the Asean Oncology summit 2009. Lancet Oncol. 2009;10:1111–1118. doi: 10.1016/S1470-2045(09)70241-4. - DOI - PubMed
    1. Krishnan S, Dawson LA, Seong J, Akine Y, Beddar S, Briere TM, Crane CH, Mornex F. Radiotherapy for hepatocellular carcinoma: an overview. Ann Surg Oncol. 2008;15:1015–1024. doi: 10.1245/s10434-007-9729-5. - DOI - PubMed
    1. Choi GH, Han DH, Kim DH, Choi SB, Kang CM, Kim KS, Choi JS, Park YN, Park JY, Kim DY, Han KH, Chon CY, Lee WJ. Outcome after curative resection for a huge (≥10 cm) hepatocellualr carcinoma and prognostic significance of gross tumor classification. Am J Surg. 2009;198(5):693–701. doi: 10.1016/j.amjsurg.2008.09.019. - DOI - PubMed
    1. Pandey D, Lee KH, Wai CT, Wagholikar G, Tan KC. Long term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection. Ann Surg Oncol. 2007;14:2817–2823. doi: 10.1245/s10434-007-9518-1. - DOI - PubMed
    1. Yamashita Y, Taketomi A, Shirabe K, Aishima S, Tsuijita E, Morita K, Kayahima H, Maehara Y. Outcome of hepatic resection for huge hepatocellular carcinoma (≥10 cm in diameter) J Surg Oncol. 2011;104:292–298. doi: 10.1002/jso.21931. - DOI - PubMed

MeSH terms